Volumetric

YC W20 · Acquired · Volumetric builds living multicellular tissues with a focus on the…

Competitors

Companies closest to Volumetric
Company	Category	Status	Program
Future FieldsShared: biotech, multicellular, scienceActiveOther	Other	Active	YCS20
Trestle BiotherapeuticsShared: biotech, tissue, functionActiveOther	Other	Active	YCW21
Pandorum TechnologiesShared: human tissue, technologyNot statedOther	Other	Not stated	500 Global2018
Parallel BioShared: drug development, biotech, testingActiveAI	AI	Active	YCS21

Adjacent

Companies next to Volumetric
Company	Category	Status	Program
Andson BiotechShared: drug development, biotech, healthcareActiveOther	Other	Active	YCW22
ACXShared: biotech, healthcare, technologyActiveOther	Other	Active	YCS24
Velorum TherapeuticsShared: biotech, healthcare, breakthroughActiveOther	Other	Active	YCW24
TwentyTwoShared: biotech, drug, biologyActiveAI	AI	Active	YCS25
Verge GenomicsShared: human tissue, drug, biologyActiveAI	AI	Active	YCS15

Also from W20

All of W20

Company	Category	Status
AIOSBuilding AI-native infrastructure for the next era of care.ActiveAI	AI	Active
Algen BiotechnologiesUsing CRISPR to find treatments for cancer and inflammationActiveAI	AI	Active
Altay TherapeuticsAltay develops disease-modifying therapies targeting transcription…ActiveAI	AI	Active
DatasaurDatasaur builds private AI/agents for enterprise/governmentActiveAI	AI	Active
SegmedReal-World Data for Health InnovationActiveAI	AI	Active
UrbanKisaanFoundation models and autonomous chambers for plant biologyActiveAI	AI	Active

About Volumetric

About Us Volumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells. Our Technology and Approach We have invented a suite of breakthrough 3D bioprinting technologies, featured on the cover of Science, that can build human tissue with complex blood vessel networks. We are leveraging this technology in the short term to build patient-specific tissues for drug safety and efficacy testing. Patient cells are taken from a biopsy, added to our proprietary 3D printed tissues, and then drug compounds are injected through the blood vessel network to mimic actual drug delivery in humans. Our vision is that our technology will provide rigorous, reproducible, and predictive outcomes for patients, resulting in drastically improved outcomes for diseases like cancer. More broadly, we see the full potential of our mission as being able to produce functional tissue and organ replacements for diseased or damaged vital organs in the body such as the lung, liver, pancreas, kidney, and heart.

YC batch: W20 · Winter 2020
Status, per YC: Acquired
Category: Other
Team size: 5
Location: Houston, TX, USA
Checked: 34m ago

YC tags: Biotech, Healthcare

Volumetric in W20: 228 companies, 29% AI

Volumetric: questions

Which YC batch was Volumetric in?

Volumetric was in Y Combinator's Winter 2020 batch (W20).

Is Volumetric still active?

Y Combinator lists Volumetric as acquired.

Where is Volumetric based?

Volumetric lists Houston, TX, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.